TFE3 nuclear expression as a novel biomarker of ovarian sclerosing stromal tumors and associated with its histological morphology

Table 1 Clinical features of SSTs

Case	Age (years)	Gross	CA199 (U/ml)	CA125 (U/ml)	Size (mm)	Menstruation	Endometrium	Management	Outcome Period	Follow-up (months)
1	23	cystic	2	36.4	60	normal	normal	UO	NED	19
2	17	solid	4.83	457.8↑	14	normal	normal	UO	NED	58
3	26	solid	ND	ND	160	normal	normal	UO	NED	84
4	26	solid	ND	ND	45	normal	normal	UO	NED	82
5	39	solid	< 2	32.2	80	irregular	normal	UO	NED	79
6	29	solid	ND	ND	60	normal	normal	UO	NED	52
7	33	solid	36.82	17.2	50	irregular	atypical hyperlasia	UO	NED	81
8	23	solid	ND	ND	25	normal	normal	UO	NED	52

SSTs Sclerosing stromal tumors, CA 199 Cancer antigen 199, CA 125 Cancer antigen 125, ND no detection, UO Unilateral, oophorectomy, NED No evidence of disease

ISSN: 1757-2215